IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, June 2023

Developing Spion-Based Nanocarriers for Targeted Tumor Therapy with Reduced Doxorubicin Cardiotoxicity

Syed Ansar Ahmed Syed Jafar[1] and Dr. Bharat Wasudeo Tekade[2]
Research Scholar, Department of Pharmacy[1]
Research Guide, Department of Pharmacy[2]
Sunrise University, Alwar, Rajasthan, India

Abstract: *Tumor therapy using chemotherapy, particularly doxorubicin (DOX), remains a cornerstone in cancer treatment. However, the clinical efficacy of DOX is often limited by its off-target toxicity, notably cardiotoxicity. This paper explores the development of superparamagnetic iron oxide nanoparticle (SPION)-based nanocarriers as a promising strategy for targeted tumor therapy with the objective of minimizing DOX-induced cardiotoxicity. We discuss the rationale behind SPION-based nanocarriers, their unique properties, and their potential to enhance drug delivery specificity while mitigating systemic side effects. Additionally, we delve into recent advancements in nanocarrier design, targeting strategies, and preclinical studies that demonstrate the potential of this approach. Ultimately, the development of SPION-based nanocarriers represents a promising avenue for improving the safety and efficacy of DOX-based tumor therapy.*

Keywords: Tumor

I. INTRODUCTION

Cancer remains a leading cause of morbidity and mortality worldwide, necessitating the continual exploration of innovative therapeutic strategies. Chemotherapy, particularly anthracyclines like doxorubicin (DOX), has been a mainstay in cancer treatment for decades due to its broad-spectrum anticancer activity. Nevertheless, the clinical use of DOX is significantly hindered by its dose-limiting cardiotoxicity, which can lead to irreversible cardiac damage and heart failure.

The development of drug delivery systems that can target tumors while sparing healthy tissues has emerged as a promising approach to enhance the therapeutic index of chemotherapeutic agents like DOX. Superparamagnetic iron oxide nanoparticles (SPIONs) have garnered considerable attention in this context due to their unique magnetic properties, biocompatibility, and versatility in drug delivery.

Properties and Advantages of SPION-Based Nanocarriers

SPIONs are nanoscale magnetic particles composed of iron oxide (Fe3O4 or Fe2O3) with a diameter typically less than 100 nm. Their superparamagnetic behavior allows for controlled manipulation within the body using external magnetic fields. SPION-based nanocarriers offer several advantages for targeted tumor therapy:

a. **Enhanced drug delivery:** SPIONs can encapsulate and carry therapeutic payloads, such as DOX, within their core. The magnetic properties of SPIONs facilitate site-specific drug delivery by guiding the nanocarriers to the tumor site using external magnets.
b. **Reduced systemic toxicity:** By concentrating drug delivery to the tumor site, SPION-based nanocarriers can reduce systemic drug exposure, potentially mitigating the cardiotoxicity associated with DOX.
c. **Imaging capabilities:** SPIONs possess intrinsic contrast-enhancing properties in magnetic resonance imaging (MRI), allowing for real-time monitoring of drug delivery and tumor response.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, June 2023

Nanocarrier Design and Targeting Strategies

Nanocarrier design and targeting strategies are crucial components of developing effective drug delivery systems, particularly when using superparamagnetic iron oxide nanoparticles (SPIONs) for targeted tumor therapy. These strategies aim to improve the specificity of drug delivery to the tumor site while minimizing off-target effects. Here are some key considerations in nanocarrier design and targeting strategies:

Surface Functionalization:

- **Coating Materials:** Surface modification with biocompatible materials, such as polyethylene glycol (PEG), improves the stability and circulation time of SPION-based nanocarriers by reducing clearance by the immune system.
- **Stealth Properties:** PEGylation, in particular, imparts stealth properties to nanocarriers, reducing opsonization and prolonging their circulation in the bloodstream.

Active Targeting:

- **Ligand Conjugation:** Attaching specific ligands, such as antibodies, peptides, or small molecules, to the surface of nanocarriers enables active targeting of tumor cells. These ligands should bind to receptors or antigens overexpressed on the tumor cell surface.
- **Enhanced Specificity:** Active targeting enhances the specificity of drug delivery by ensuring that nanocarriers primarily accumulate in the tumor tissue rather than healthy organs.

Passive Targeting (EPR Effect):

- **Enhanced Permeability and Retention (EPR) Effect:** Nanocarriers can exploit the EPR effect, which is characterized by the leaky vasculature and impaired lymphatic drainage in tumor tissues. This effect allows nanocarriers to passively accumulate in the tumor site due to their small size.
- **Size Optimization:** Tuning the size of SPION-based nanocarriers to the range suitable for EPR-mediated accumulation is essential for passive targeting.

Stimuli-Responsive Systems:

- **pH-Responsive Systems:** Designing nanocarriers that respond to the acidic pH of the tumor microenvironment can enable controlled drug release within the tumor. pH-sensitive polymers or coatings can be used for this purpose.
- **Temperature-Responsive Systems:** Thermosensitive nanocarriers can release drugs when exposed to a specific temperature, often achieved through external heating techniques like hyperthermia.

Multi-Functional Nanocarriers:

- **Combination Therapy:** Incorporating multiple therapeutic agents or modalities (e.g., chemotherapy and phototherapy) within the same nanocarrier can enhance treatment efficacy and overcome drug resistance.
- **Imaging Modalities:** Nanocarriers can be designed to carry contrast agents for imaging purposes, such as MRI or fluorescence imaging, allowing for real-time monitoring of drug delivery and tumor response.

Magnetic Targeting:

- **External Magnetic Fields:** SPION-based nanocarriers can be guided to the tumor site using external magnets, enhancing their specificity. This approach is particularly valuable for tumors located near the body surface or in accessible locations.
- Safety Considerations:
- **Biocompatibility:** Ensuring the safety and biocompatibility of SPIONs and nanocarrier components is critical to prevent adverse effects in vivo.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, June 2023

Regulatory Aspects:

- **Clinical Translation:** Successful translation from bench to bedside requires rigorous preclinical testing and adherence to regulatory guidelines.
- **Manufacturability:** Developing scalable and reproducible manufacturing processes for SPION-based nanocarriers is essential for clinical production.

Preclinical Studies and Promising Results

Recent preclinical studies utilizing SPION-based nanocarriers for DOX delivery have shown promising results. These studies have demonstrated improved tumor accumulation, enhanced therapeutic efficacy, and reduced cardiotoxicity compared to free DOX. Furthermore, the ability to visualize nanocarrier distribution using MRI has provided valuable insights into drug delivery kinetics.

II. CONCLUSION

The development of SPION-based nanocarriers represents a promising approach to improve the safety and efficacy of DOX-based tumor therapy. These nanocarriers offer enhanced drug delivery, reduced systemic toxicity, and imaging capabilities, making them a versatile platform for targeted tumor therapy. Continued research and collaboration between multidisciplinary teams are essential to address remaining challenges and advance SPION-based nanocarriers toward clinical application, ultimately improving the outlook for cancer patients while minimizing the cardiotoxicity associated with DOX.

REFERENCES

[1]. Freeman, M., Arrott, A., Watson, J., 1960. Magnetism in medicine. Journal of Applied Physics 31, S404-S405.
[2]. Gaihre, B., Aryal, S., Khil, M.S., Kim, H.Y., 2008. Encapsulation of Fe3O4 in gelatinnanoparticles: Effect of different parameters on size and stability of the colloidal dispersion. Journal of microencapsulation 25, 21-30.
[3]. Gamonpilas, C., Pongjaruvat, W., Methacanon, P., Seetapan, N., Fuongfuchat, A., Klaikherd, A., 2013. Effects of cross-linked tapioca starches on batter viscosity andoil absorption in deep-fried breaded chicken strips. Journal of food engineering 114, 262-268.
[4]. Gewirtz, D., 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology 57, 727-741.
[5]. Ghosh, S., Yesilyurt, V., Savariar, E.N., Irvin, K., Thayumanavan, S., 2009. Redox, ionic strength, and pH sensitive supramolecular polymer assemblies. Journal of Polymer Science Part A: Polymer Chemistry 47, 1052-1060.
[6]. Gonçalves, P.M., Noreña, C.P.Z., da Silveira, N.P., Brandelli, A., 2014. Characterization of starch nanoparticles obtained from Araucaria angustifolia seeds by acid hydrolysis and ultrasound. LWT-Food Science and Technology 58, 21-27.
[7]. Grote, C., Lazik, W., Heinze, T., 2003. Tartaric Acid Starch Ether: A Novel Biopolymer-Based Polyelectrolyte. Macromolecular rapid communications 24, 927- 931.
[8]. Gupta, A.K., Curtis, A.S., 2004. Lactoferrin and ceruloplasmin derivatized superparamagnetic iron oxide nanoparticles for targeting cell surface receptors. Biomaterials 25, 3029-3040.
[9]. Gupta, A.K., Gupta, M., 2005a. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 26, 1565-1573.
[10]. Gupta, A.K., Gupta, M., 2005b. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26, 3995-4021.
[11]. Han, J., Guo, X., Lei, Y., Dennis, B.S., Wu, S., Wu, C., 2012. Synthesis and characterization of selenium–chondroitin sulfate nanoparticles. Carbohydratepolymers 90, 122-126.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, June 2023

[12]. Hanahan, D., Weinberg, R.A., 2000. The hallmarks of cancer. cell 100, 57-70. Hentze, M.W., Muckenthaler, M.U., Andrews, N.C., 2004. Balancing acts: molecular control of mammalian iron metabolism. cell 117, 285-297.

[13]. Herrero, A.M., Carmona, P., Jiménez-Colmenero, F., Ruiz-Capillas, C., 2014. Polysaccharide gels as oil bulking agents: Technological and structural properties. Food Hydrocolloids 36, 374-381.

[14]. Hilger, I., Hiergeist, R., Hergt, R., Winnefeld, K., Schubert, H., Kaiser, W.A., 2002. Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Investigative radiology 37, 580-586.

[15]. Hobbs, S.K., Monsky, W.L., Yuan, F., Roberts, W.G., Griffith, L., Torchilin, V.P., Jain, R.K., 1998. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proceedings of the National Academy of Sciences 95, 4607-4612.

[16]. Homayouni, A., Azizi, A., Ehsani, M., Yarmand, M., Razavi, S., 2008. Effect of microencapsulation and resistant starch on the probiotic survival and sensory properties of synbiotic ice cream. Food chemistry 111, 50-55.

[17]. Ip, A.C.-F., Tsai, T.H., Khimji, I., Huang, P.-J.J., Liu, J., 2014. Degradable starch nanoparticle assisted ethanol precipitation of DNA. Carbohydrate polymers 110, 354- 359.

[18]. Iyer, A.K., Khaled, G., Fang, J., Maeda, H., 2006. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug discovery today 11, 812- 818.

[19]. Jain, A., Thakur, K., Sharma, G., Kush, P., Jain, U.K., 2016. Fabrication, characterization and cytotoxicity studies of ionically cross-linked docetaxel loaded chitosan nanoparticles. Carbohydrate polymers 137, 65-74.

[20]. Jain, R.K., Stylianopoulos, T., 2010. Delivering nanomedicine to solid tumors. Nature reviews Clinical oncology 7, 653-664.

[21]. Jain, T.K., Morales, M.A., Sahoo, S.K., Leslie-Pelecky, D.L., Labhasetwar, V., 2005. Iron oxide nanoparticles for sustained delivery of anticancer agents. Molecular pharmaceutics 2, 194-205.

[22]. Jain, T.K., Richey, J., Strand, M., Leslie-Pelecky, D.L., Flask, C.A., Labhasetwar, V., 2008. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials 29, 4012-4021.

[23]. Jang, S.H., Wientjes, M.G., Lu, D., Au, J.L.-S., 2003. Drug delivery and transport to solid tumors. Pharmaceutical research 20, 1337-1350.

[24]. Jiang, J., Tong, X., Morris, D., Zhao, Y., 2006. Toward photocontrolled release using light-dissociable block copolymer micelles. Macromolecules 39, 4633-4640.

[25]. Jiang, W., Xie, H., Ghoorah, D., Shang, Y., Shi, H., Liu, F., Yang, X., Xu, H., 2012. Conjugation of functionalized SPIONs with transferrin for targeting and imaging brain glial tumors in rat model. PLoS One 7, e37376.